• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

eFoodSafety Announces Human Clinical Trials to Study the Effectiveness of ColdZap(TM) on Patients Suffering With the Common Cold

Posted on: Monday, 23 July 2007, 09:11 CDT

eFoodSafety.com, Inc. (OTCBB:EFSF) is pleased to announce that Bucks County Clinical Research, a FDA-approved research facility (bccrinc.com), has agreed to study the efficacy of eFoodSafety's ColdZap™, a proprietary formulation which was developed by the company's wholly owned subsidiary Knock-Out Technologies, Ltd. for the treatment of the common cold.

ColdZap™ is an all-natural compound that already has been shown to have anti-microbial effectiveness on the viruses associated with the common cold. The results in laboratory testing show that ColdZap™ kills the viruses and prevents their spread.

The clinical trials are intended to determine if ColdZap™ will lessen the severity and reduce the duration of the common cold. Since the formulation of ColdZap™ has already been shown to be safe to ingest, human clinical trials testing the product's efficacy treating the common cold can proceed immediately.

According to February 2003 research published by the University of Michigan, the common cold carries a "$40 billion price tag" in the U.S. economy alone. Reported to be the most commonly occurring illness in humans, the report projected that approximately 500 million colds occur in the U.S. per year, with an average of 2.5 colds per person per year.

Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "With ColdZap™, we're moving far beyond the treatment of cold symptoms. We're attacking the virus, the underlying cause of a cold. With anticipated positive results from these clinical trials, we expect to make a major impact in reducing the $40 billion price tag associated with the common cold. Obviously, with a positive outcome in human trials, ColdZap™ could quickly become a multi-million product for eFoodSafety."

Bucks County Clinical Research will be conducting its clinical trials on patients presenting symptoms of the common cold. Each patient will be given a packet of ColdZap™ to be used as the only remedy to treat this illness. Patients will be required to document their clinical response measured by improvement of their symptoms and reduction in duration of their illness. With positive results, eFoodSafety will quickly move ColdZap™ into the market beginning with existing retail distribution channels for other eFoodSafety products.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) -- EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn™-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line. The Company is also owner of Cinnergen™, a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol™, a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category